Diane V. Havlir, MD

Chief, HIV/AIDS Division, SFGH UCSF
Principal Investigator, MU-UCSF Collaboration


E-mail Address:  dhavlir@php.ucsf.edu


Professional Interests:
HIV therapeutic strategies HIV and co-infections (TB and Malaria)

diane

Current Main Activities:
Research: Strategies to address the intersection of HIV, TB, Malaria in Subsarahan Africa.
Service:  Chair, TB/HIV Working Group of the Stop TB Partnership International AIDS Society (IAS) Governing Council WHO Committee on Antiretroviral Guidelines for Resource Limited Settings
Teaching: Mentoring U.S. and Ugandan junior investigators in patient based and translational research.

 

Education and Training:
Fellowship, Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, 1988-1990

MD, Duke University Medical School, Durham, North Carolina, 1984

Categorical Internal Medicine Residency, University of California, San Francisco, 1984-1987

BA, St. Olaf College, Northfield, Minnesota, 1980

 

Key Publications:

1. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir DV, Kamya MR. Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children. N Engl J Med. 2012 Nov 29; 367(22):2110-8.


2. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012 Nov 13; 26(17):2121-33.


3. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos K, Deeks SG, Gandhi M, Havlir DV. The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels among HIV-Infected Patients Entering Care with a CD4 Count Greater than 500/µl in a Public Health Setting. Clin Infect Dis. 2012 Sep 5.


4. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir DV, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Aug 22.


5. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400.


6. Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark T, Ades V, Plenty A, Charlebois E, Ruel T, Kamya M, Havlir DV, Cohan D. Maternal Nutritional Status Predicts Adverse Birth Outcomes among HIV-Infected Rural Ugandan Women Receiving Combination Antiretroviral Therapy. PLoS One. 2012; 7(8):e41934.


7. Havlir DV, Beyrer C. The beginning of the end of AIDS? N Engl J Med. 2012 Aug 23; 367(8):685-7.


8. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2012 Jun; 20(2):48-60.


9. Jordan MR, Bennett DE, Wainberg MA, Havlir DV, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011. Clin Infect Dis. 2012 May; 54 Suppl 4:S245-9.


10. Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, Rosenthal PJ, Dorsey G, Achan J, Akello C, Kamya MR, Wong JK. Neurocognitive and Motor Deficits in HIV-Infected Ugandan Children With High CD4 Cell Counts. Clin Infect Dis. 2012 Apr; 54(7):1001-9.


11. Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc. 2012; 15(2):17396.


12. Kay J, Wanzira H, Sandison T, Kakuru A, Bigira V, Kamya M, Homsy J, Tappero JW, Havlir DV, Dorsey G, Ruel T. Virologic Suppression in Nevirapine-Exposed HIV-Infected Infants Initiating Antiretroviral Therapy in Rural Uganda. J Trop Pediatr. 2012 Jun; 58(3):194-9.


13. Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, Mugyenyi P, Boom WH, Mugerwa RD, Havlir DV, Whalen CC. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4? T-cell counts of = 350 cells/µL. J Infect Dis. 2011 Sep 15; 204(6):884-92.


14. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois ED, Feeney ME. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011 Sep; 53(6):592-9.


15. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, Charlebois E, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis. 2011 Apr 1; 203(7):992-1001.


16. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK, Achan J. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011 Jan; 56(1):44-50.


17. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, Akello C, Cao H, Dorsey G, Rosenthal PJ, Ssewanyana I, Kamya MR, Havlir DV. Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):330-5.


18. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010 Oct; 14(10):1295-302.


19. Charlebois ED, Havlir DV. "A bird in the hand...": a commentary on the test and treat approach for HIV. Arch Intern Med. 2010 Aug 9; 170(15):1354-6.


20. Chamie G, Charlebois ED, Srikantiah P, Walusimbi-Nanteza M, Mugerwa RD, Mayanja H, Okwera A, Whalen CC, Havlir DV. Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis. 2010 Aug 1; 51(3):359-62.


21. Bebell LM, Pilcher CD, Dorsey G, Havlir DV, Kamya MR, Busch MP, Dunn Williams J, Nugent CT, Bentsen C, Rosenthal PJ, Charlebois ED. Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS. 2010 Jul 31; 24(12):1945-52.


22. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, Ruel T, Kateera F, Meya DN, Havlir DV, Rosenthal PJ, Dorsey G. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010; 9:177.


23. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S245-54.


24. Boivin MJ, Ruel TD, Boal HE, Bangirana P, Cao H, Eller LA, Charlebois E, Havlir DV, Kamya MR, Achan J, Akello C, Wong JK. HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS. 2010 May 15; 24(8):1163-70.


25. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One. 2010; 5(2):e9138.


26. Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, Havlir DV, Rosenthal PJ, Dorsey G, Clark TD, Cohan D. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J. 2009; 8:254.


27. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir DV, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 1; 51(4):424-9.


28. Ruel T, Ssewanyana I, Achan J, Gasasira A, Kamya MR, Kekitiinwa A, Wong JK, Cao H, Havlir DV, Charlebois ED. Dynamics of T cell activation accompanying CD4 recovery in antiretroviral treated HIV-infected Ugandan children. Clin Immunol. 2009 Jun; 131(3):410-4.


29. Davis JL, Huang L, Kovacs JA, Masur H, Murray P, Havlir DV, Worodria WO, Charlebois ED, Srikantiah P, Cattamanchi A, Huber C, Shea YR, Chow Y, Fischer SH. Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis. Clin Infect Dis. 2009 Mar 15; 48(6):725-32.


30. Ssewanyana I, Baker CA, Ruel T, Bousheri S, Kamya M, Dorsey G, Rosenthal PJ, Charlebois E, Havlir DV, Cao H. The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda. AIDS Res Hum Retroviruses. 2009 Jan; 25(1):65-71.


31. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir DV. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis. 2008 Dec; 12(12):1370-5.


32. Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, Kayanja HK, Mugerwa RD, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis. J Acquir Immune Defic Syndr. 2008 Dec 1; 49(4):458-60.


33. Havlir DV. HIV integrase inhibitors--out of the pipeline and into the clinic. N Engl J Med. 2008 Jul 24; 359(4):416-8.


34. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30.


35. Ruel TD, Achan J, Gasasira AF, Charlebois ED, Mehbratu T, Rosenthal PJ, Dorsey G, Kamya MR, Kekitiinwa A, Wong J, Havlir DV. HIV RNA suppression among HIV-infected Ugandan children with measles. J Acquir Immune Defic Syndr. 2008 Jun 1; 48(2):225-7.


36. Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, Charlebois E, Staedke SG, Kekitiinwa A, Rosenthal PJ, Havlir DV, Dorsey G. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008 Apr 1; 46(7):985-91.


37. Bebell LM, Gasasira A, Kiggundu M, Dokomajilar C, Kamya MR, Charlebois ED, Havlir DV, Rosenthal PJ, Dorsey G. HIV-1 infection in patients referred for malaria blood smears at government health clinics in Uganda. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):624-30.


38. Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG, Gasasira A, Kamya M, Nakiwala J, Achan J, Charlebois E, Havlir DV, Cao H. Profile of T cell immune responses in HIV-infected children from Uganda. J Infect Dis. 2007 Dec 1; 196(11):1667-70.


39. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, Charlebois ED, Rosenthal PJ, Havlir DV, Dorsey G. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007 Oct 1; 21(15):2059-66.


40. Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS. 2007 Sep 12; 21(14):1972-4.


41. Gasasira AF, Dorsey G, Kamya MR, Havlir DV, Kiggundu M, Rosenthal PJ, Charlebois ED. False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol. 2006 Aug; 44(8):3021-4.


42. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006 Jan 1; 193(1):9-15.